Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Change in Accured Expenses (2016 - 2025)

Traws Pharma (TRAW) has disclosed Change in Accured Expenses for 14 consecutive years, with $189000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 122.0% to $189000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $132000.0, a 102.35% increase, with the full-year FY2024 number at -$5.2 million, down 792.14% from a year prior.
  • Change in Accured Expenses was $189000.0 for Q3 2025 at Traws Pharma, up from $74000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $631000.0 in Q2 2022 to a low of -$4.1 million in Q2 2024.
  • A 5-year average of -$376052.6 and a median of -$69000.0 in 2023 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: surged 589.15% in 2022, then tumbled 1144.93% in 2024.
  • Traws Pharma's Change in Accured Expenses stood at $383000.0 in 2021, then surged by 59.27% to $610000.0 in 2022, then plummeted by 87.7% to $75000.0 in 2023, then skyrocketed by 528.0% to $471000.0 in 2024, then tumbled by 59.87% to $189000.0 in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Change in Accured Expenses are $189000.0 (Q3 2025), $74000.0 (Q2 2025), and -$602000.0 (Q1 2025).